AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (Currently amended) A method of increasing the sensitivity of cancer cells or a tumour to a chemotherapeutic agent by contacting said cells or tumour with an isoflavonoid compound of formula (VI) or (VII):



(VI)



(VII)

~~(I):~~



(I)

~~in which~~ wherein

R_1, R_2 and Z are independently hydrogen, hydroxy, OR_9, $OC(O)R_{10}$, $OS(O)R_{10}$, CHO, $C(O)R_{10}$, COOH, CO_2R_{10}, $CONR_3R_4$, alkyl, haloalkyl, arylalkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylaryl, alkoxyaryl, thio, alkylthio, amino, alkylamino, dialkylamino, nitro or halo, or

R_2 is as previously defined, and R_1 and Z taken together with the carbon atoms to which they are attached form a five-membered ring selected from

, or

R_1 is as previously defined, and R_2 and Z taken together with the carbon atoms to which they are attached form a five-membered ring selected from

~~and~~

W is R_1, ~~A is hydrogen, hydroxy, NR_3R_4 or thio, and B is selected from~~



~~, or~~

~~W is R_1, and A and B taken together with the carbon atoms to which they are attached form a six-membered ring selected from~~



~~or~~

~~W, A and B taken together with the groups to which they are associated are selected from~~



~~, or~~

~~W and A taken together with the groups to which they are associated are selected from~~



~~and B is selected from~~



~~wherein~~

R_3 is hydrogen, alkyl, arylalkyl, alkenyl, aryl, an amino acid, $C(O)R_{11}$ where R_{11} is hydrogen, alkyl, aryl, arylalkyl or an amino acid, or CO_2R_{12} where ~~R12~~R_{12} is hydrogen, alkyl, haloalkyl, aryl or arylalkyl,

R_4 is hydrogen, alkyl or aryl, or

R_3 and R_4 taken together with the nitrogen to which they are attached comprise pyrrolidinyl or piperidinyl,

~~R_5 is hydrogen, $C(O)R_{11}$ where R_{11} is as previously defined, or CO_2R_{12} where R_{12} is as previously defined,~~

R_6 is hydrogen, hydroxy, alkyl, aryl, amino, thio, NR_3R_4, COR_{11} where R_{11} is as previously defined, CO_2R_{12} where R_{12} is as previously defined or $CONR_3R_4$,

~~R_7 is hydrogen, $C(O)R_{11}$ where R_{11} is as previously defined, alkyl, haloalkyl, alkenyl, aryl, arylalkyl or $Si(R_{13})_3$ where each R_{13} is independently hydrogen, alkyl or aryl,~~

~~R_8 is hydrogen, hydroxy, alkoxy or alkyl,~~

R_9 is alkyl, haloalkyl, aryl, arylalkyl, $C(O)R_{11}$ where R_{11} is as previously defined, or $Si(R_{13})_3$ where R_{13} ~~is as previously defined~~ where each R_{13} is independently hydrogen, alkyl or aryl,

R_{10} is hydrogen, alkyl, haloalkyl, amino, aryl, arylalkyl, an amino acid, alkylamino or dialkylamino,

the drawing "---" represents either a single bond or a double bond,

T is independently hydrogen, alkyl or aryl,

~~X is O, NR_4, or S, and~~

~~Y is~~



~~wherein~~

R_{14}, and R_{15} ~~and R_{16}~~ are independently hydrogen, hydroxy, OR_9, $OC(O)R_{10}$, $OS(O)R_{10}$, CHO, $C(O)R_{10}$, COOH, CO_2R_{10}, $CONR_3R_4$, alkyl, haloalkyl, arylalkyl, alkenyl, alkynyl, aryl, heteroaryl, thio, alkylthio, amino, alkylamino, dialkylamino, nitro or halo, or ~~any two of~~ R_{14}, and R_{15} ~~and R_{16}~~ are fused together to form a cyclic alkyl, aromatic or heteroaromatic structure,

and pharmaceutically acceptable salts thereof, and

wherein the chemotherapeutic agent is platinum-based or anti-mitotic agent.

2. (Currently amended) A method of claim 1, wherein prior to the contacting, ~~the sensitivity of~~ the cancer cells or tumour were/was not sensitive to the chemotherapeutic agent ~~is restored~~.

3. (Currently amended) A method of claim 1, wherein the compound of formula [[(I)]](VI) or (VII) is administered to a subject in need of such treatment.

4. (Currently amended) A combination therapy for the treatment or prophylaxis of cell proliferation, cancer or a disease associated with oxidant stress comprising administering to a subject a therapeutically effective amount of a compound of formula [[(I)]](VI) or (VII) ~~as defined in claim 1~~ and a chemotherapeutic agent:


(VI)


(VII)

wherein

R_1, R_2 and Z are independently hydrogen, hydroxy, OR_9, $OC(O)R_{10}$, $OS(O)R_{10}$, CHO, $C(O)R_{10}$, COOH, CO_2R_{10}, $CONR_3R_4$, alkyl, haloalkyl, arylalkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylaryl, alkoxyaryl, thio, alkylthio, amino, alkylamino, dialkylamino, nitro or halo, or

R_2 is as previously defined, and R_1 and Z taken together with the carbon atoms to which they are attached form a five-membered ring selected from


, or

R_1 is as previously defined, and R_2 and Z taken together with the carbon atoms to which they are attached form a five-membered ring selected from


.

W is R_1,

R_3 is hydrogen, alkyl, arylalkyl, alkenyl, aryl, an amino acid, $C(O)R_{11}$ where R_{11} is hydrogen, alkyl, aryl, arylalkyl or an amino acid, or CO_2R_{12} where R_{12} is hydrogen, alkyl, haloalkyl, aryl or arylalkyl,

R_4 is hydrogen, alkyl or aryl, or

R_3 and R_4 taken together with the nitrogen to which they are attached comprise pyrrolidinyl or piperidinyl,

R_5 is hydrogen, hydroxy, alkyl, aryl, amino, thio, NR_3R_4, COR_{11} where R_{11} is as previously defined, CO_2R_{12} where R_{12} is as previously defined or $CONR_3R_4$,

R_9 is alkyl, haloalkyl, aryl, arylalkyl, $C(O)R_{11}$ where R_{11} is as previously defined, or $Si(R_{13})_3$ where R_{13} where each R_{13} is independently hydrogen, alkyl or aryl,

R_{10} is hydrogen, alkyl, haloalkyl, amino, aryl, arylalkyl, an amino acid, alkylamino or dialkylamino,

the drawing "---" represents either a single bond or a double bond,

T is independently hydrogen, alkyl or aryl,

R_{14}, and R_{15} are independently hydrogen, hydroxy, OR_9, $OC(O)R_{10}$, $OS(O)R_{10}$, CHO, $C(O)R_{10}$, COOH, CO_2R_{10}, $CONR_3R_4$, alkyl, haloalkyl, arylalkyl, alkenyl, alkynyl, aryl, heteroaryl, thio, alkylthio, amino, alkylamino, dialkylamino, nitro or halo, or R_{14} and R_{15} are fused together to form a cyclic alkyl, aromatic or heteroaromatic structure,

and pharmaceutically acceptable salts thereof, and

wherein the chemotherapeutic agent is platinum-based or anti-mitotic agent.

5. (Canceled).

6. (Previously Presented) A method of claim 4, wherein the cancer is selected from breast cancer, prostatic cancer, testicular cancer, ovarian cancer, uterine cancer, pancreatic cancer and colorectal cancer.

7. (Original) A method claim 6, wherein the cancer is selected from ovarian cancer, prostatic cancer and pancreatic cancer.

8. (Currently amended) A method of claim 4, wherein the administration of the compound of formula [[(I)]](VI) or (VII) precedes the administration of the chemotherapeutic agent.

9. (Currently amended) A method of claim 4, wherein the administration of the compound of formula [[(I)]](VI) or (VII) and the chemotherapeutic agent is simultaneous.

10. (Previously Presented) A method claim 4, wherein the combination therapy follows observed resistance by cancer cells or tumour to a chemotherapeutic agent.

11.-12. (Canceled).

13. (Previously Presented) A method of claim 4, wherein the chemotherapeutic agent is cisplatin, paclitaxel or carboplatin.

14.-22. (Canceled).

23. (Currently amended) A pharmaceutical composition comprising a compound of formula [[(I)]](VI) or (VII) ~~of claim 1~~ and a chemotherapeutic agent:



(VI)



(VII)

wherein

R_1, R_2 and Z are independently hydrogen, hydroxy, OR_9, $OC(O)R_{10}$, $OS(O)R_{10}$, CHO, $C(O)R_{10}$, COOH, CO_2R_{10}, $CONR_3R_4$, alkyl, haloalkyl, arylalkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylaryl, alkoxyaryl, thio, alkylthio, amino, alkylamino, dialkylamino, nitro or halo, or

R_2 is as previously defined, and R_1 and Z taken together with the carbon atoms to which they are attached form a five-membered ring selected from

, or

R_1 is as previously defined, and R_2 and Z taken together with the carbon atoms to which they are attached form a five-membered ring selected from



,

W is R_1,

R_3 is hydrogen, alkyl, arylalkyl, alkenyl, aryl, an amino acid, $C(O)R_{11}$ where R_{11} is hydrogen, alkyl, aryl, arylalkyl or an amino acid, or CO_2R_{12} where R_{12} is hydrogen, alkyl, haloalkyl, aryl or arylalkyl,

R_4 is hydrogen, alkyl or aryl, or

R_3 and R_4 taken together with the nitrogen to which they are attached comprise pyrrolidinyl or piperidinyl,

R_6 is hydrogen, hydroxy, alkyl, aryl, amino, thio, NR_3R_4, COR_{11} where R_{11} is as previously defined, CO_2R_{12} where R_{12} is as previously defined or $CONR_3R_4$,

R_9 is alkyl, haloalkyl, aryl, arylalkyl, $C(O)R_{11}$ where R_{11} is as previously defined, or $Si(R_{13})_3$ where R_{13} where each R_{13} is independently hydrogen, alkyl or aryl,

R_{10} is hydrogen, alkyl, haloalkyl, amino, aryl, arylalkyl, an amino acid, alkylamino or dialkylamino,

the drawing "---" represents either a single bond or a double bond,

T is independently hydrogen, alkyl or aryl,

R_{14}, and R_{15} are independently hydrogen, hydroxy, OR_9, $OC(O)R_{10}$, $OS(O)R_{10}$, CHO, $C(O)R_{10}$, COOH, CO_2R_{10}, $CONR_3R_4$, alkyl, haloalkyl, arylalkyl, alkenyl, alkynyl, aryl, heteroaryl, thio, alkylthio, amino, alkylamino, dialkylamino, nitro or halo, or R_{14} and R_{15} are fused together to form a cyclic alkyl, aromatic or heteroaromatic structure,

and pharmaceutically acceptable salts thereof, and

wherein the chemotherapeutic agent is platinum-based or anti-mitotic agent.

24. (Previously Presented): The pharmaceutical composition of claim 23, wherein said chemotherapeutic agent is cisplatin, paclitaxel or carboplatin.

25. (Canceled).

26. (New): The method of claim 1, wherein the cancer cells and tumour are/is hormone-responsive.

27. (New): The method of claim 1, wherein the cancer is selected from breast cancer, prostatic cancer, testicular cancer, ovarian cancer, uterine cancer, pancreatic cancer and colorectal cancer.

28. (New): The method of claim 1, wherein the cancer cells and tumour are/is from ovarian, prostate or pancreatic cancer.